Pharmacokinetics and tolerability of intravenous trecovirsen (GEMρ91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects

Journal of Clinical Pharmacology

Volumn 39, Issue 1, 1999, Pages 47-54

  Séréni, Daniel ^a   Tubiana, Roland ^b   Lascoux, Caroline ^a   Katlama, Christine ^b   Taulera, Oliver ^a   Bourque, Andre ^c   Cohen, Aharon ^c   Dvorchik, Barry ^c   Martin, R Russell ^c   Tournerie, Christophe ^e   Gouyette, Alain ^d   Schechter, Paul J ^c  

^a Université Paris Descartes   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HYBRIDON INC   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; TRECOVIRSEN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PARTIAL THROMBOPLASTIN TIME; PHARMACOKINETICS; PLASMA CLEARANCE;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEADACHE; HIV SEROPOSITIVITY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PARTIAL THROMBOPLASTIN TIME; THIONUCLEOTIDES;

EID: 0032921468     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922007552     Document Type: Article

References (19)

1. ® 91 - an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS. Antisense Res Dev 1992;2:261-266.
2. Lisziewicz J, Sun D, Wiechold FF, Thierry AR, Lusso P, Tang J, et al: Antisense oligodeoxynucleotide phosphorothioate complementary to gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc Natl Acad Sci USA 1994;91:7942-7946.
3. ® 91) in HIV-infected subjects. Clin Pharmacol Ther 1995;58:44-53.
4. Padmapriya AA, Tang JY, Agrawal S: Large scale synthesis, purification and analysis of oligonucleotide phosphorothioates. Antisense Res Dev 1994;4:185-199.
5. Bourque AJ, Cohen AS: Quantitative analysis of phosphorothioate oligonucleotides in biological fluids using fast anion-exchange chromatography. J Chromatogr 1993;617:43-49.
6. Bourque AJ, Cohen AS: Quantitative analysis of phosphorothioate oligonucleotides in biological fluids using direct injection fast anion-exchange chromatography and capillary gel electrophoresis. J Chromatogr 1994;662:343-349.
7. Galbraith WM, Hobson WC, Giclas PC, Schechter P, Agrawal S: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 1994;4:201-206.
8. Flexner C, Barditch-Crovo PA, Kornhauser DM, Farzadegan H, Nerhood LJ, Chaisson RE, et al: Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob Agents Chemother 1991;35:2544-2550.
9. Cornish KG, Iversen P, Smith L, Arneson M, Bayeer E: Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. Pharmacol Commun 1993;3:239-242.
10. Agrawal S, Temsamani J, Galbraith W, Tang J: Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 1995;28:7-17.
11. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 1993;267:1181-1190.
12. 3H-labeled oligo-nucleotides: I. comparison of a phosphodiester and a phosphorothioate. Molec Pharmacol 1994;45:932-943.
13. Srinivasan SK, Iverson P: Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J Clin Lab Analysis 1995;9:129-137.
14. Zhang R, Diasio RB, Lu Z, Liu T, Jiang Z, Galbraith WM, et al: Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phospborothioate (GEM® 91) developed as a therapeutic agent for human immunodeficiency virus Type-1. Biochem Pharmacol 1995;49:929-939.
15. Agrawal S, Temsamani J, Tang JY: Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 1991;88:7595-7599.
16. Crooke ST, Graham MJ, Zuckerman JE, Brooks D, Conklin BS, Cummins LL, et al: Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther 1996;277:923-937.
17. Bishop MR, Iverson, PL, Bayever, E, Sharp JG, Greiner TC, Copple BL, et al: Phase I trial of an antisense oligonucleotide OL(1)p53 in hematological malignancies. J Clin Oncol 1996;14:1320-1326.
18. Iverson P: In vivo studies with phosphorothioate oligonucleotides: pharmacokinetic prologue. Anti-Cancer Drug Design 1991;6:531-538.
19. Bayever E, Iverson PL, Bishop MR, Sharp JG, Tewary HK, Arneson MA, et al: Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome. Initial results of a phase I trial. Antisense Res & Dev 1993;3:383-390.